Clinical Trials Browser

Phase 2 × Recruiting × Lymphoma, B-Cell × Clear all

NCT05615636 2026-03-16

A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL

Phase 2 Recruiting

Hodgkin Disease, Lymphoma, B-Cell

NCT07125872 2026-03-16

Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma

Phase 2 Recruiting

Lymphoma, B-Cell

NCT06526793 2026-02-25

SOUNDTRACK-B

Phase 2 Recruiting

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, B-Cell

NCT06484920 2026-02-10

A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL

Phase 2 Recruiting

Hodgkin Disease, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT06350318 2026-02-05

Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas

Phase 2 Recruiting

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT07077512 2026-01-21

Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma

Phase 2 Recruiting

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT07162181 2026-01-21

Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT07097363 2026-01-15

Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma

Phase 2 Recruiting

Burkitt Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT06213311 2026-01-14

A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma

Phase 2 Recruiting

Lymphoma, B-Cell

NCT06365671 2026-01-06

CAR-T Following ASCT for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (R/R B-NHL) With High-Risk Prognostic Factors

Phase 2 Recruiting

Lymphoma, B-Cell

NCT04792502 2025-12-30

Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma

Phase 2 Recruiting

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT06508931 2025-12-18

DALY PED

Phase 2 Recruiting

Lymphoma, B-Cell

NCT06300528 2025-12-03

Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas

Phase 2 Recruiting

Recurrence, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT05821088 2025-11-20

Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma

Phase 2 Recruiting

Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT05453396 2025-10-16

Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies

Phase 2 Recruiting

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT06052826 2025-10-06

Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study

Phase 2 Recruiting

LymphoidPlasma cell

Multiple Myeloma, Lymphoma, B-Cell

NCT07081022 2025-08-21

JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma

Phase 2 Recruiting

Lymphoma, B-Cell

NCT06954805 2025-05-02

Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)

Phase 2 Recruiting

Lymphoma, Lymphoproliferative Disorders, Lymphoma, B-Cell

NCT04792489 2025-04-24

DALY II USA/ MB-CART2019.1 for DLBCL

Phase 2 Recruiting

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Central Nervous System Neoplasms, Lymphoma, Mantle-Cell

NCT06158386 2025-02-19

Chidamide Combined With Linperlisibon for the Treatment of Refractory/Relapsed Follicular Lymphoma

Phase 2 Recruiting

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT05281809 2025-01-13

Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT06698484 2024-11-21

CAR-T for NHL

Phase 2 Recruiting

Lymphoma, B-Cell

NCT06566586 2024-11-20

A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma

Phase 2 Recruiting

Lymphoma, B-Cell

NCT06534762 2024-08-02

Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study

Phase 2 Recruiting

BreastGastrointestinalHead & NeckLymphoidSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Lung Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Lymphoma, B-Cell, Dendritic Cell Sarcoma, Interdigitating, Triple Negative Breast Neoplasms

NCT06462248 2024-06-17

Anti-CD19 Chimeric Antigen Receptor Modified T-cell (CAR-T) Therapy for Treatment of B-cell Hematological Malignancies

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Lymphoid, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT06415708 2024-05-16

Obinutuzumab Combined With Bendamustine in the Treatment of Mature B-cell Lymphoma

Phase 2 Recruiting

Lymphoma, B-Cell

NCT06381830 2024-04-24

Clinical Study of CAR-T Cell Therapy Following ASCT for R/R B-cell Non-Hodgkin's Lymphoma

Phase 2 Recruiting

Lymphoma, B-Cell

NCT06081478 2023-10-13

CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia

Phase 2 Recruiting

Burkitt Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT05436223 2022-07-05

Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma

Phase 2 Recruiting

Recurrence, Lymphoma, B-Cell